Objective:

To propose a sustainable pricing framework for repurposed drugs, specifically focusing on the newly approved ophthalmic formulation of bevacizumab and its implications for healthcare affordability.

Key Findings:

• The estimated sustainable price range for repurposed bevacizumab is €73 to €177 per injection, significantly lower than the current list price of Lytenava, which is around £470 per injection.
• Manufacturing costs and patient population size are the primary drivers of price.
• There is a significant gap between the modelled cost-based price and the current list price of Lytenava, highlighting the need for pricing discussions.

Interpretation:

Current pricing dynamics for repurposed drugs can discourage investment or lead to high prices that burden healthcare systems, indicating a need for more transparent pricing structures that align with affordability.

Limitations:

• The study may not account for all variables influencing drug pricing, such as market competition and regulatory changes.
• Assumptions made in the cost model may not reflect real-world complexities, potentially affecting the accuracy of the price estimates.

Conclusion:

There is a need for pricing models that reflect the lower development costs of repurposed drugs while ensuring incentives for innovation are maintained, balancing affordability with the need for continued investment in drug development.